Ua hoʻopaʻa inoa ʻo MGC Pharmaceuticals Ltd. i kahi ʻaelike hāʻawi kūʻokoʻa me Sciensus Rare, kahi ʻāpana o ka hui mālama ola olakino UK, ʻo Sciensus, no ka hāʻawi ʻana iā CannEpil® a me CogniCann® i nā ʻāina nui ʻEulopa a me UK.
ʻO ka ʻaelike no ka hāʻawi ʻana i nā ʻāina ʻEulopa nui a me UK no CannEpil®, i hoʻohana ʻia e mālama i ka Drug Resistant Epilepsy, a me CogniCann®, i hoʻohana ʻia e mālama i nā maʻi me ka Dementia a me ka maʻi o Alzheimer.
ʻO Sciensus Rare kahi hui lāʻau lapaʻau honua i hoʻokumu ʻia ma Netherlands, ʻoihana kūikawā i ka hoʻolako ʻana i nā lāʻau lapaʻau maʻi maʻi ma o nā hoʻokolohua hoʻokolohua decentralized a me nā papahana hoʻonaʻauao olakino, me ka ʻoi aku o 30-makahiki o ka ʻike i ka hāʻawi ʻana i nā lawelawe mālama olakino, a me ka hoʻonui ʻana i ka loaʻa olakino no nā huahana ma ʻEulopa Komohana.
Ma lalo o nā ʻōlelo o ka ʻaelike hoʻoili, ua koho ʻia ʻo Sciensus Rare i mea hoʻolaha kūʻokoʻa o CannEpil® a me CogniCann® ma Denmark, Farani, Italia, Sepania, Luxembourg, a me United Kingdom, kekahi o nā mākeke lāʻau lapaʻau kiʻekiʻe loa ma ka honua, no ka mea. he kau mua 4 makahiki. Ma hope o nā mahina 12 mua o ka ʻaelike, e kau ʻia ʻo Sciensus Rare i nā koi kauoha kūʻai liʻiliʻi e mālama i kona kūlana hoʻolaha kūʻokoʻa. Ua ʻae nā ʻaoʻao e hoʻomau ʻo MGC Pharma i ke kuleana no ka ʻimi ʻana i ka ʻae ʻana i ka mākeke ma kēia mau ʻāina, ʻoiai ʻo Sciensus Rare ke kuleana no nā noi i nā Polokalamu Early Access a me Named Patient Programs.
Ua ʻōlelo ʻo Roby Zomer, Luna Hoʻokele a me Luna Nui o MGC Pharma: "He ʻoihana lawelawe lāʻau lapaʻau maikaʻi loa ʻo Sciensus Rare, me ka ʻike a me ka ʻike e pono ai e hoʻonui i ke komo ʻana i ka lāʻau lapaʻau no CannEpil® a me CogniCann® i kēlā poʻe maʻi i nele.
ʻO kēia kahi hana koʻikoʻi i ka hoʻonui ʻana i ka loaʻa ʻana o ka poʻe maʻi i kā mākou huahana lāʻau, a kau i kahi hoʻolālā lōʻihi e kūkulu i nā ʻoihana hoʻolaha i koi ʻia ma Western Europe, kekahi o nā mākeke lāʻau koʻikoʻi o ka honua.
Ua ʻōlelo ʻo Gareth Williams, Pelekikena o Sciensus Rare: "ʻOliʻoli loa mākou i ka hana pū ʻana me MGC Pharmaceuticals i loko o ka mākeke cannabis lapaʻau hoihoi honua a ke kakali nei i ke kākoʻo ʻana i nā kauka i loaʻa iā CannEpil® a me CogniCann®.
He aha e lawe ʻia mai kēia ʻatikala:
- Under the terms of the distribution agreement, Sciensus Rare has been appointed the exclusive distributor of CannEpil® and CogniCann® in Denmark, France, Italy, Spain, Luxembourg, and the United Kingdom, some of the most advanced pharmaceutical markets in the world, for an initial 4-year term.
- ʻO Sciensus Rare kahi hui lāʻau lapaʻau honua i hoʻokumu ʻia ma Netherlands, ʻoihana kūikawā i ka hoʻolako ʻana i nā lāʻau lapaʻau maʻi maʻi ma o nā hoʻokolohua hoʻokolohua decentralized a me nā papahana hoʻonaʻauao olakino, me ka ʻoi aku o 30-makahiki o ka ʻike i ka hāʻawi ʻana i nā lawelawe mālama olakino, a me ka hoʻonui ʻana i ka loaʻa olakino no nā huahana ma ʻEulopa Komohana.
- This is another important step in widening patient access to our pharmaceutical products, and puts in place a long term plan to build the distribution networks required in Western Europe, one of the most important pharmaceutical markets in the world.
